Active Pharmaceutical Ingredients (APIs)

  • Rasagiline Mesylate

    • API Product   :   

      Rasagiline Mesylate

    • CEP   :   

      -

    • WCC   :   

      ?

    • Therapeutic Use    :   

      Anti-Parkinson Drugs

    • Originator   :   

      Lundbeck

    • CAS No.    :   

      136236-51-6

    • Trade Name.   :   

      AZILECT

    • Molecular Weight   :   

      171.238 g/mol

    • Molecular Formula   :   

      C12H13N

    Application

    Rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. It can help improve symptoms such as shakiness, stiffness, and difficulty moving. It can also help reduce the amount of "off" time (periods of slow movement or stiffness).

    General Description

    Rasagiline (Azilect, TVP-1012, N-propargyl-1(R)-aminoindan[1]) is an irreversible inhibitor of monoamine oxidase-B[2] used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases.[3] The racemic form of the drug was invented by Aspro Nicholas in the early 1970s. Moussa B.H. Youdim identified it as a potential drug for Parkinson's disease, and working with collaborators at Technion – Israel Institute of Technology in Israel and the drug company, Teva Pharmaceutical, identified the R-isomer as the active form of the drug.